Affymetrix Launches Solution to Enable Cancer Researchers to Rapidly Map the Functional Impact of DNA Alterations on Gene Exp...
November 12 2014 - 5:30AM
Business Wire
Affymetrix (NASDAQ:AFFX) announced today the launch of
Concurrent Molecular Analysis Profiling (CoMAP™) capability, which
enables cancer researchers to gain rapid insight into the
functional impact of DNA copy number alterations by combining
whole-genome copy number data with gene expression profiles to
easily and cost-effectively visualize and identify cancer driver
events.
Whole-genome DNA analysis of cancer samples has shown that copy
number alterations affect more of the genome than any other DNA
abnormality. Many of these alterations are “drivers” of cancer,
while others are just “passenger” events. Deciphering which of the
DNA alterations are “driver” or “passenger” events has been a
challenge. Having the ability to concurrently correlate genome-wide
gene expression changes with copy number alterations can help to
rapidly identify and prioritize the number of potential driver
events, which in turn can lead to the identification of functional
biomarkers. This is particularly valuable to researchers studying
“C class” tumors, which are characterized by functional copy number
changes as opposed to somatic mutations.
The CoMAP capability is a new functionality included in
Affymetrix’ new Chromosome Analysis Suite (ChAS) 3.0 Software that
enables researchers to easily and quickly analyze and visualize the
functional impact of copy number changes on gene expression in
cancer samples, including FFPE tissue. This capability
instantaneously combines and correlates whole-genome copy number
data with mRNA and miRNA data generated from Affymetrix’ assays
such as OncoScan® FFPE Assay Kit, GeneChip® Human Transcriptome
Array 2.0, and GeneChip® miRNA 4.0 Array respectively. This
approach enables researchers to go from samples to insights in just
three days. The correlation maps may be generated for all RefSeq
genes or a customized gene list.
“Despite billions of dollars that are spent every year on cancer
research, cancer remains one of the leading causes of death
worldwide. Affymetrix is committed to enabling translational
science by providing practical and cost-effective tools so that
researchers can rapidly translate their discovery into improved
cancer diagnosis and therapy,” said Andy Last, PhD, Chief Operating
Officer of Affymetrix.
For more information on ChAS 3.0 with the CoMAP capability,
visit www.affymetrix.com/comap.
PLEASE NOTE: Affymetrix®, the Affymetrix logo,
CoMAP™, GeneChip®, and OncoScan® are the property
of Affymetrix, Inc. All other trademarks are the property
of their respective owners.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness. The
Company provides leadership and support, partnering with customers
in pharmaceutical, diagnostic, and biotechnology companies, as well
as leading academic, government, and non-profit research institutes
in their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
65,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, Ohio,
San Diego, Vienna, and Singapore. The Company has about 1,100
employees worldwide and maintains sales and distribution operations
across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2013, and other SEC reports for subsequent
quarterly periods.
Affymetrix:Media Contact:Mindy Lee-Olsen,
408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestor Contact:Doug
Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024